Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
For patients undergoing front-line treatment for chronic myeloid leukemia, generic treatment may be less effective than the branded agent, researchers suggest, but treatment efficacy is maintained in patients who switch from a branded to a generic formulation.
Study findings suggest that the depth of molecular response to imatinib achieved by a patient with chronic myeloid leukemia may influence the relationship between a fluctuating response to treatment and the likelihood of developing resistance to the tyrosine kinase inhibitor.
The ENESTfreedom study of patients who stopped first-line nilotinib after achieving a sustained deep molecular response has shown that around half of chronic myeloid leukemia patients continue in remission.
Chronic myeloid leukemia patients with high CD62L T-cell expression and low soluble CD62L plasma levels at diagnosis have the best chance of achieving a deep molecular response to first-line therapy with tyrosine kinase inhibitors, study findings indicate.
Patients with chronic myeloid leukemia who successfully discontinue imatinib treatment have a higher proportion of mature natural killer cells than those who experience early relapse, a substudy of the EURO-SKI data shows.
Researchers have identified six different patterns of somatic mutation acquisition, persistence, and clearance in patients with chronic myeloid leukemia, with a significant link between these and tyrosine kinase inhibitor therapy response.